KR101419963B1 - 선택적인 케모카인 조절 - Google Patents

선택적인 케모카인 조절 Download PDF

Info

Publication number
KR101419963B1
KR101419963B1 KR1020097007490A KR20097007490A KR101419963B1 KR 101419963 B1 KR101419963 B1 KR 101419963B1 KR 1020097007490 A KR1020097007490 A KR 1020097007490A KR 20097007490 A KR20097007490 A KR 20097007490A KR 101419963 B1 KR101419963 B1 KR 101419963B1
Authority
KR
South Korea
Prior art keywords
metal
titanium
blood
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097007490A
Other languages
English (en)
Korean (ko)
Other versions
KR20090069293A (ko
Inventor
라르스 브루스
스톨레 페테르 륑스타도스
Original Assignee
프롭휘 메드 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39184028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101419963(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프롭휘 메드 아베 filed Critical 프롭휘 메드 아베
Publication of KR20090069293A publication Critical patent/KR20090069293A/ko
Application granted granted Critical
Publication of KR101419963B1 publication Critical patent/KR101419963B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/06—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group B01J20/04
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
KR1020097007490A 2006-09-12 2007-09-11 선택적인 케모카인 조절 Expired - Fee Related KR101419963B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84376006P 2006-09-12 2006-09-12
US60/843,760 2006-09-12
PCT/SE2007/000785 WO2008033069A1 (en) 2006-09-12 2007-09-11 Selective chemokine modulation

Publications (2)

Publication Number Publication Date
KR20090069293A KR20090069293A (ko) 2009-06-30
KR101419963B1 true KR101419963B1 (ko) 2014-07-30

Family

ID=39184028

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097007490A Expired - Fee Related KR101419963B1 (ko) 2006-09-12 2007-09-11 선택적인 케모카인 조절

Country Status (17)

Country Link
US (3) US8784845B2 (cg-RX-API-DMAC10.html)
EP (1) EP2068895B1 (cg-RX-API-DMAC10.html)
JP (1) JP5290179B2 (cg-RX-API-DMAC10.html)
KR (1) KR101419963B1 (cg-RX-API-DMAC10.html)
CN (1) CN101573126B (cg-RX-API-DMAC10.html)
AU (1) AU2007295138B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0716728A2 (cg-RX-API-DMAC10.html)
CA (1) CA2663259C (cg-RX-API-DMAC10.html)
ES (1) ES2401031T3 (cg-RX-API-DMAC10.html)
IL (1) IL197562A (cg-RX-API-DMAC10.html)
MX (1) MX2009002699A (cg-RX-API-DMAC10.html)
MY (1) MY148756A (cg-RX-API-DMAC10.html)
NO (1) NO341876B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ576190A (cg-RX-API-DMAC10.html)
RU (1) RU2446809C2 (cg-RX-API-DMAC10.html)
SG (1) SG174094A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008033069A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE531319C2 (sv) 2007-02-22 2009-02-24 Tigran Technologies Ab Publ Porös implantatgranul
US9957311B2 (en) 2013-12-20 2018-05-01 Tikomed Ab Surface-binding peptide
CN104020297B (zh) * 2014-06-10 2016-12-07 上海交通大学医学院 用于结核分枝杆菌感染检测及临床治疗效果监测的试剂盒及其用途
JP6631499B2 (ja) * 2016-12-27 2020-01-15 トヨタ自動車株式会社 ハイブリッド車両の制御装置
CA3183415A1 (en) 2020-05-11 2021-11-18 Minnetronix Neuro, Inc. Filtering cassettes and filtering systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012180A2 (en) 1999-08-12 2001-02-22 UNIVERSITé LAVAL Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce
US20030055106A1 (en) 1999-08-12 2003-03-20 Robert Faure Therapeutic uses of peroxometallic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2252729B (en) 1991-02-13 1994-11-09 Bharat Sridhar Pancham Vitamin and/or mineral containing pharmaceutical compositions
EP0686848A1 (en) 1994-05-09 1995-12-13 Shiseido Company Limited Liquid chromatograph having a micro and semi-micro column
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6527951B1 (en) * 2000-11-16 2003-03-04 Waters Investments Limited Chromatographic column
US20050119105A1 (en) * 2002-01-18 2005-06-02 Schott Ag Glass-ceramic composite containing nanoparticles
DE10201747C1 (de) 2002-01-18 2003-08-14 Schott Glas Glas-Keramik-Komposit, Verfahren zu seiner Herstellung und Verwendungen
US20100018928A1 (en) * 2004-11-16 2010-01-28 Waters Investments Limited Device for performing separations and methods of making and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012180A2 (en) 1999-08-12 2001-02-22 UNIVERSITé LAVAL Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce
US20030055106A1 (en) 1999-08-12 2003-03-20 Robert Faure Therapeutic uses of peroxometallic compounds

Also Published As

Publication number Publication date
CN101573126B (zh) 2012-04-25
EP2068895A4 (en) 2009-12-23
EP2068895A1 (en) 2009-06-17
SG174094A1 (en) 2011-09-29
US9649426B2 (en) 2017-05-16
RU2009113579A (ru) 2010-10-20
RU2446809C2 (ru) 2012-04-10
CN101573126A (zh) 2009-11-04
US8784845B2 (en) 2014-07-22
WO2008033069A1 (en) 2008-03-20
US20100203089A1 (en) 2010-08-12
NZ576190A (en) 2011-06-30
NO20091420L (no) 2009-06-11
JP2010503666A (ja) 2010-02-04
AU2007295138A1 (en) 2008-03-20
IL197562A (en) 2013-12-31
BRPI0716728A2 (pt) 2017-06-13
US20140302149A1 (en) 2014-10-09
NO341876B1 (no) 2018-02-12
WO2008033069A8 (en) 2009-07-23
CA2663259A1 (en) 2008-03-20
US9656015B2 (en) 2017-05-23
KR20090069293A (ko) 2009-06-30
US20140299548A1 (en) 2014-10-09
MY148756A (en) 2013-05-31
ES2401031T3 (es) 2013-04-16
AU2007295138B2 (en) 2012-10-04
IL197562A0 (en) 2009-12-24
JP5290179B2 (ja) 2013-09-18
CA2663259C (en) 2017-01-03
EP2068895B1 (en) 2012-12-12
MX2009002699A (es) 2009-06-11

Similar Documents

Publication Publication Date Title
Daniel et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis
EP2687219A1 (en) Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
Hamilton et al. Endotoxin, TNF-alpha, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis
Yli-Karjanmaa et al. Topical administration of a soluble TNF inhibitor reduces infarct volume after focal cerebral ischemia in mice
CN110799186A (zh) 治疗炎性疾病的组合物和方法
US9656015B2 (en) Selective chemokine modulation
Wang et al. Honokiol possesses potential anti-inflammatory effects on rheumatoid arthritis and GM-CSF can be a target for its treatment
CN114099481A (zh) 雾化吸入型糖皮质激素纳米药物及其制备方法和应用
US20220395540A1 (en) Treatment of covid-19 lung injury using umbilical cord plasma based compositions
Kaminska et al. Serum cytokine level and production of reactive oxygen species (ROS) by blood neutrophils from a schizophrenic patient with hypersensitivity to neuroleptics
JPH11505247A (ja) １５−リポキシゲナーゼを誘導するためのｉｌ−１３の使用
CN115684594A (zh) Trem-2在制备多发性硬化症的治疗药物和/或诊断试剂中的应用
WO2017093048A1 (en) Method and devices for producing serum
CN107050436B (zh) Mbl在制备预防或治疗效应t细胞引发疾病药物中的应用
EP4578454A1 (en) Compositions comprising platelet derived extracellular vesicles
Rashid et al. In vitro expression and inhibition of procoagulant activity produced by bovine alveolar macrophages and peripheral blood cells
CN111000978B (zh) Tlt-2在制备治疗结核病药物中的应用
He et al. CD137 Signaling Plays a Crucial Role in the Parasite Eradication and Inflammation Development During the Acute Infection of Toxoplasma gondii
Simatupang et al. COMPARISON OF PROTEIN C LEVELS IN HIV PATIENTS WITH CD4 VALUES< 200 CELLS/µL AND CD4 VALUES≥ 200 CELLS/µL IN HAJI ADAM MALIK GENERAL HOSPITAL MEDAN
SHANSHAN et al. SAT-456 Effect of FangjiHuangqi decoction on IL-6 and TGF-β1 secretion by HMC after intervention of inflammatory factors secreted by lymphocytes based on p38MAPK signaling pathway
Elhelbawy et al. Chemokine receptor 2 (CCR2) G190A polymorphism in chronic renal failure patients requiring hemodialysis
van der Zee et al. THE EFFECT OF LQGV ON PERIPHERAL BLOOD NEuTROPHILS IN MICE: A PILOT STuDY

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170621

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180703

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190702

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200710

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200710

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000